Estudo randomizado | Efetividade da terapia com etoposídeo e cisplatina vs. irinotecano e cisplatina para pacientes com carcinoma neuroendócrino avançado do sistema digestório.
23 Ago, 2022 | 16:33h
Comentário no Twitter
JCOG1213 (TOPIC NEC), the first randomized phase III trial in advanced neuroendocrine carcinoma of the digestive system, shows no significant difference in overall survival for etoposide+cisplatin versus irinotecan+cisplatin therapy https://t.co/JTELRlzTzi #GICSM pic.twitter.com/AQT8U4yd3l
— JAMA Oncology (@JAMAOnc) August 18, 2022